We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

125 hedge funds and large institutions have $861M invested in Pliant Therapeutics in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 20

83% more call options, than puts

Call options by funds: $4.53M | Put options by funds: $2.48M

35% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 31

14% more funds holding

Funds holding: 110 → 125 (+15)

13% more funds holding in top 10

Funds holding in top 10: 8 → 9 (+1)

1.55% less ownership

Funds ownership: 93.23% → 91.68% (-1.6%)

7% less capital invested

Capital invested by funds: $925M → $861M (-$63.8M)

Holders
125
Holders Change
+15
Holders Change %
+13.64%
% of All Funds
2.01%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.14%
New
37
Increased
42
Reduced
31
Closed
20
Calls
$4.53M
Puts
$2.48M
Net Calls
+$2.06M
Net Calls Change
-$448K

Top Buyers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
+$19.3M
2
Citadel Advisors
Citadel Advisors
Florida
+$12M
3
PCH
Polar Capital Holdings
United Kingdom
+$11.1M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.58M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$7.31M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP III
Massachusetts
-$41.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$35.4M
3
RG
Redmile Group
California
-$13.2M
4
Invesco
Invesco
Georgia
-$5.7M
5
CA
CHI Advisors
New York
-$5.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$6.76M +$454K +21,740 +7%
Deutsche Bank
27
Deutsche Bank
Germany
$6.09M +$140K +6,690 +2%
FIM
28
Fernwood Investment Management
Massachusetts
$5.89M +$1.71M +81,816 +37%
Axa
29
Axa
France
$5.27M -$543K -25,995 -9%
State Street
30
State Street
Massachusetts
$5.04M +$988K +47,244 +22%
SCM
31
Silverarc Capital Management
Massachusetts
$4.2M +$161K +7,681 +4%
Two Sigma Investments
32
Two Sigma Investments
New York
$4.2M -$639K -30,562 -12%
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$4.13M -$31.7K -1,514 -0.7%
Millennium Management
34
Millennium Management
New York
$4M +$269K +12,849 +7%
Russell Investments Group
35
Russell Investments Group
United Kingdom
$3.54M -$177K -8,478 -4%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$3.43M +$1.6M +76,600 +76%
Voloridge Investment Management
37
Voloridge Investment Management
Florida
$3.34M +$1.44M +68,683 +66%
Charles Schwab
38
Charles Schwab
California
$3.34M +$79K +3,778 +2%
MIM
39
Monashee Investment Management
Massachusetts
$2.9M +$1.05M +50,000 +50%
Goldman Sachs
40
Goldman Sachs
New York
$2.85M +$936K +44,791 +44%
EP
41
Eversept Partners
New York
$2.66M -$3.28M -156,680 -53%
Morgan Stanley
42
Morgan Stanley
New York
$2.2M -$2.08M -99,713 -47%
BDFN
43
Bond & Devick Financial Network
Minnesota
$2.13M – – –
AllianceBernstein
44
AllianceBernstein
Tennessee
$2.09M +$27.3K +1,307 +1%
ACM
45
Altium Capital Management
New York
$1.93M -$2.4M -115,000 -53%
N
46
Natixis
France
$1.91M +$2.06M +98,600 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$1.7M +$1.84M +88,100 New
Northern Trust
48
Northern Trust
Illinois
$1.57M +$524K +25,071 +45%
Federated Hermes
49
Federated Hermes
Pennsylvania
$1.54M – – –
Qube Research & Technologies (QRT)
50
Qube Research & Technologies (QRT)
United Kingdom
$1.49M +$1.05M +50,169 +186%
1
2
3 4 5

PLRX Hedge Fund Activity: Q4 2022 in Review

125 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q4 2022, worth a combined $861M — down 6.9% from $925M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new PLRX positions and 20 closed out — a net gain of 17 holders — while 42 added to existing stakes and 31 trimmed.

The largest buyer was Casdin Capital, adding an estimated $19.3M. The largest seller was TRV GP III, cutting an estimated $41.8M.

  • 125 institutional investors held Pliant Therapeutics (PLRX) as of Q4 2022, up from 110 in Q3 2022.
  • Funds reported $861M of Pliant Therapeutics stock for Q4 2022, down 6.9% quarter-over-quarter.
  • 37 funds opened new Pliant Therapeutics positions in Q4 2022 and 20 closed out, a net change of +17 holders.
  • The largest Pliant Therapeutics buyer in Q4 2022 was Casdin Capital, an estimated $19.3M added.
  • The largest Pliant Therapeutics seller in Q4 2022 was TRV GP III, an estimated $41.8M sold.

Based on aggregated 13F filings for Q4 2022.